Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome

World Journal of Gastroenterology

Volumn 21, Issue 25, 2015, Pages 7860-7868

  Kargiotis, Konstantinos ^a   Athyros, Vasilios G ^a   Giouleme, Olga ^a   Katsiki, Niki ^a   Katsiki, Evangelia ^b   Anagnostis, Panagiotis ^a   Boutari, Chrysoula ^a   Doumas, Michael ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University and Hippokration General Hospital   (Greece)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dyslipidaemia; Fasting blood glucose; Metabolic syndrome; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Rosuvastatin; Serum uric acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; COLLAGEN; FENOFIBRATE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; ROSUVASTATIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; URIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DETERIORATION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATOGRAPHY; HUMAN; HUMAN TISSUE; HYPERTENSION; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER HISTOLOGY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; OPEN STUDY; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BIOPSY; BLOOD; DIAGNOSTIC IMAGING; DRUG EFFECTS; GREECE; LIVER; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; BIOMARKERS; BIOPSY; BLOOD GLUCOSE; FEMALE; GREECE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; LIVER; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; ROSUVASTATIN CALCIUM; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY; URIC ACID;

EID: 84936806639     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i25.7860     Document Type: Article

References (43)

1. Baran B, Akyüz F. Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? World J Gastroenterol 2014;20:14219-14229 [PMID: 25339808 DOI: 10.3748/wjg.v20.i39.14219]
2. Jiang CM, Pu CW, Hou YH, Chen Z, Alanazy M, Hebbard L. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World J Gastroenterol 2014;20:16464-16473 [PMID: 25469014]
3. Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol 2014;20:13306-13324 [PMID: 25309067]
4. Bader T. Yes! Statins can be given to liver patients. J Hepatol 2012;56:305-307 [PMID: 21963520 DOI: 10.1016/j.jhep. 2011.08.016]
5. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681 [PMID: 21067804 DOI: 10.1016/S0140-6736 (10) 61350-5]
6. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-1922 [PMID: 21109302 DOI: 10.1016/S0140-6736 (10) 61272-X]
7. Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, Liberopoulos EN, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011;7:796-805 [PMID: 22291824 DOI: 10.5114/aoms.2011.25554]
8. Kargiotis K, Katsiki N, Athyros VG, Giouleme O, Patsiaoura K, Katsiki E, Mikhailidis DP, Karagiannis A. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol 2014;12:505-511 [PMID: 24805248]
9. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752 [PMID: 16157765 DOI: 10.1161/CIRCULATIONAHA.105.169404]
10. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239 [PMID: 15249516 DOI: 10.1161/01. CIR.0000133317.49796.0E]
11. Tenenbaum A, Fisman EZ. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol 2010;9:24 [PMID: 20550659 DOI: 10.1186/1475-2840-9-24]
12. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321 [PMID: 15915461 DOI: 10.1002/hep. 20701]
13. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685 [PMID: 20427778 DOI: 10.1056/NEJMoa0907929]
14. Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, Kastelein JJ, Holme I, Pedersen TR. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013;168:3846-3852 [PMID: 24001698 DOI: 10.1016/j.ijcard.2013.06.024]
15. Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, Takahashi S, Chayama K. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2012;42:1065-1072 [PMID: 22583925 DOI: 10.1111/j.1872-034X.2012.01034.x]
16. Hyogo H, Ikegami T, Tokushige K, Hashimoto E, Inui K, Matsuzaki Y, Tokumo H, Hino F, Tazuma S. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2011;41:1057-1065 [PMID: 21951922 DOI: 10.1111/j.1872-034X.2011.00849.x]
17. Clarke JD, Hardwick RN, Lake AD, Canet MJ, Cherrington NJ. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression. J Pharmacol Exp Ther 2014;348:452-458 [PMID: 24403518 DOI: 10.1124/jpet.113.211284]
18. Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, Cherrington NJ. Synergistic interaction between genetics and disease on pravastatin disposition. J Hepatol 2014;61:139-147 [PMID: 24613363 DOI: 10.1016/j.jhep. 2014.02.021]
19. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 2009;43:990-994 [PMID: 19448566 DOI: 10.1097/MCG.0b013e31819c392e]
20. Wang W, Zhao C, Zhou J, Zhen Z, Wang Y, Shen C. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis. PLoS One 2013;8:e76538 [PMID: 24098525 DOI: 10.1371/journal. pone.0076538]
21. Riche DM, Fleming JW, Malinowski SS, Black CA, Miller KH, Wofford MR. Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome. Ann Pharmacother 2014;48:137-141 [PMID: 24259612 DOI: 10.1177/1060028013507239]
22. Neto-Ferreira R, Rocha VN, Souza-Mello V, Mandarim-De-Lacerda CA, De Carvalho JJ. Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice. Diabetol Metab Syndr 2013;5:32 [PMID: 23816341 DOI: 10.1186/1758-5996-5-32]
23. Schreuder TC, Verwer BJ, Van Nieuwkerk CM, Mulder CJ. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol 2008;14:2474-2486 [PMID: 18442193 DOI: 10.3748/wjg.14.2474]
24. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, Ishitobi T, Nonaka M, Chayama K. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008;57:1711-1718 [PMID: 19013295 DOI: 10.1016/j.metabol.2008.07.030]
25. Angelico F, Del Ben M, Pignatelli P, Violi F. Comment on "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property". Dig Liver Dis 2013;45:81-82 [PMID: 22917635 DOI: 10.1016/j.dld.2012.07.009]
26. Pignatelli P, Carnevale R, Di Santo S, Bartimoccia S, Nocella C, Vicario T, Loffredo L, Angelico F, Violi F. Rosuvastatin reduces platelet recruitment by inhibiting NADPH oxidase activation. Biochem Pharmacol 2012;84:1635-1642 [PMID: 23022230 DOI: 10.1016/j.bcp. 2012.09.011]
27. Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010;45:750-757 [PMID: 20112031 DOI: 10.1007/s00535-010-0203-y]
28. Kei A, Liberopoulos E, Elisaf M. Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia. World J Diabetes 2013;4:365-371 [PMID: 24379928 DOI: 10.4239/wjd. v4.i6.365]
29. Chen CW, Chen TC, Huang KY, Chou P, Chen PF, Lee CC. Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an asian country. PLoS One 2013;8:e71817 [PMID: 23951249 DOI: 10.1371/journal.pone.0071817]
30. Anagnostis P, Selalmatzidou D, Polyzos SA, Panagiotou A, Slavakis A, Panagiotidou A, Athyros VG, Karagiannis A, Mikhailidis DP, Kita M. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. Int J Clin Pract 2011;65:679-683 [PMID: 21564441 DOI: 10.1111/j.1742-1241.2011.02655.x]
31. Anagnostis P, Adamidou F, Slavakis A, Polyzos SA, Selalmatzidou D, Panagiotou A, Athyros VG, Karagiannis A, Kita M. Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. Open Cardiovasc Med J 2014;8:55-60 [PMID: 25110531 DOI: 10.2174/1874192401408010055]
32. D'Adamo E, Cali AM, Weiss R, Santoro N, Pierpont B, Northrup V, Caprio S. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. Diabetes Care 2010;33:1817-1822 [PMID: 20668154 DOI: 10.2337/dc10-0284]
33. Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol 2014;20:9072-9089 [PMID: 25083080 DOI: 10.3748/wjg.v20.i27.9072]
34. Malin SK, Mulya A, Fealy CE, Haus JM, Pagadala MR, Scelsi AR, Huang H, Flask CA, McCullough AJ, Kirwan JP. Fetuin-A is linked to improved glucose tolerance after short-term exercise training in nonalcoholic fatty liver disease. J Appl Physiol (1985) 2013;115:988-994 [PMID: 23928114 DOI: 10.1152/japplphysiol.00237.2013]
35. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006;55:1293-1301 [PMID: 16979398 DOI: 10.1016/j.metabol.2006.05.013]
36. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Hype-ruricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011;9:698-705 [PMID: 21388346 DOI: 10.2174/15701611179748 4152]
37. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Milionis HJ, Mikhailidis DP. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-599 [PMID: 15042535]
38. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, Tziomalos K, Ganotakis ES, Elisaf M. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-127 [PMID: 16998214 DOI: 10.1093/ndt/gfl538]
39. Athyros VG, Karagiannis A, Ganotakis ES, Paletas K, Nicolaou V, Bacharoudis G, Tziomalos K, Alexandrides T, Liberopoulos EN, Mikhailidis DP. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011;27:1659-1668 [PMID: 21714711 DOI: 10.1185/03007995.2011.595782]
40. Yoon HJ, Cha BS. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World J Hepatol 2014;6:800-811 [PMID: 25429318 DOI: 10.4254/wjh.v6.i11.800]
41. Milic S, Stimac D. Nonalcoholic fatty liver disease/steatohe-patitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012;30:158-162 [PMID: 22722431 DOI: 10.1159/000336669]
42. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231 [PMID: 11961152 DOI: 10.1056/NEJMra011775]
43. Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014;39:3-14 [PMID: 24206433 DOI: 10.1111/apt.12543]